Related Experiment Video

Updated: May 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients

Giuseppe Marazzi1, Maurizio Volterrani, Giuseppe Caminiti

  • 1Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Rome, Italy. giuseppe.marazzi@sanraffaele.it

Journal of Cardiac Failure
|August 30, 2011
PubMed

Insights

Nebivolol and carvedilol show similar long-term effectiveness in improving left ventricular ejection fraction and exercise capacity for hypertensive patients with chronic heart failure (CHF). Both medications equally benefit heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are crucial for managing chronic heart failure (CHF), improving left ventricular (LV) function and patient prognosis.
  • Different beta-blockers possess distinct pleiotropic properties that can influence cardiovascular outcomes.
  • This study investigates the comparative long-term effects of nebivolol and carvedilol in hypertensive CHF patients.

Purpose of the Study:

  • To compare the efficacy of nebivolol versus carvedilol in improving left ventricular ejection fraction (LVEF) in hypertensive CHF patients over 24 months.
  • To assess the impact of nebivolol and carvedilol on exercise capacity and clinical outcomes in this patient population.
  • To evaluate the long-term effects of these beta-blockers on heart rate and New York Heart Association (NYHA) functional class.

Main Methods:

  • An open-label, randomized study involving 160 hypertensive CHF patients with LVEF <40% (NYHA class I-III).
  • Patients received either nebivolol (10 mg/d) or carvedilol (50 mg/d) for 24 months.
  • Evaluations included clinical assessment, echocardiography, and the 6-minute walking test at baseline and end of treatment.

Main Results:

  • Both nebivolol and carvedilol significantly increased LVEF compared to baseline (p < .001 for both).
  • Significant improvements were observed in heart rate, NYHA functional class, and 6-minute walking distance in both treatment groups (p < .001).
  • Cardiac events occurred in 26% of carvedilol recipients and 22% of nebivolol recipients over 24 months.

Conclusions:

  • Nebivolol and carvedilol demonstrate comparable long-term efficacy in treating hypertensive patients with CHF.
  • Both agents effectively improve LV systolic function, exercise capacity, and clinical status.
  • The findings suggest similar therapeutic benefits between nebivolol and carvedilol in this patient cohort.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...